Novel parp inhibitors
CA 2505876 A1 · Owner: Hamamoto, Hajime · Inventors: Shiromizu, Ikuya; Hamamoto, Hajime; Kato, Kazuo
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds represented by the general formula (.IOTA.) and salts thereof; and medicinal compositions containing the same as the active ingredient: wherein R1 is H, halogeno, OH, amino, C1-4 alkyl which may be substituted with one to five halogen atoms, or C1-4 alkoxy; n is 0 to 2; R2 and R3 are each H C1-6 , alkyl, C2-4 alkenyl, or -L-Ar (wherein L is a bond or C1-6 alkylene; and Ar is a group derived from a saturated or unsaturated 5- or 6-membered ring which may contain one to three atoms selected from among N S, and O or a saturated , or unsaturated 8- to 12-membered fused-bicyclic hydrocarbon group) with the , proviso that these groups may be substituted with one or more members …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 11, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 11, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 11, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.